Your browser doesn't support javascript.
loading
Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer.
Meade, S; Gaunt, P; Hartley, A; Robinson, M; Harrop, V; Cashmore, J; Wagstaff, L; Babrah, J; Bowden, S J; Mehanna, H; Sanghera, P.
Afiliación
  • Meade S; Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
  • Gaunt P; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Hartley A; Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
  • Robinson M; School of Dental Sciences, Newcastle University, Newcastle, UK.
  • Harrop V; Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
  • Cashmore J; Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
  • Wagstaff L; Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
  • Babrah J; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Bowden SJ; CRUK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • Mehanna H; Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
  • Sanghera P; Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK. Electronic address: paul.sanghera@uhb.nhs.uk.
Clin Oncol (R Coll Radiol) ; 30(6): 366-374, 2018 06.
Article en En | MEDLINE | ID: mdl-29478732
AIMS: Oropharyngeal squamous cell carcinoma (OPSCC) can be divided into favourable and poor prognostic groups by association with human papilloma virus (HPV) and smoking. This study prospectively investigated a dose-intensified schedule in poor/intermediate prognosis OPSCC. MATERIALS AND METHODS: Patients with p16/HPV-negative or p16-positive N2b OPSCC with a greater than 10 pack-year smoking history were eligible. Patients were planned to receive 64 Gy in 25 fractions with cisplatin. The primary end point was absence of grade 3 mucositis at 3 months. RESULTS: Fifteen patients were recruited over 14 months. All patients completed a minimum of 2 years of follow-up. All patients completed full-dose radiotherapy within a median treatment time of 32 days (31-35). Grade 3 mucositis was absent in all patients at 3 months. There was one grade 4 toxicity event due to cisplatin (hypokalaemia). Complete response rates at 3 months were 100% and 93% for local disease and lymph nodes, respectively. One patient developed metastatic disease and subsequently died. Overall survival at 2 years was 93% (95% confidence interval 61-99%). CONCLUSIONS: The schedule of 64 Gy in 25 fractions with concomitant chemotherapy is tolerable in patients with poor and intermediate prognosis OPSCC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papillomaviridae / Neoplasias Orofaríngeas / Quimioradioterapia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papillomaviridae / Neoplasias Orofaríngeas / Quimioradioterapia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido